Vertex To Launch Phase III Trial Of Telaprevir In Treatment-failure HCV Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech gets U.S. and EU approval to test HCV drug in full range of patients who failed in prior treatment.
You may also be interested in...
GlobeImmune’s Hep C Vaccine Posts Positive Phase II Data
GlobeImmune responds to calls to “show me the data,” increasing its chances of a partnership.
GlobeImmune’s Hep C Vaccine Posts Positive Phase II Data
GlobeImmune responds to calls to “show me the data,” increasing its chances of a partnership.
Market Likes Telaprevir For Twice-daily Dosing
Positive assessment follows market uncertainty as Vertex issues incorrect data, then makes correction.